The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Subscribe To Our Newsletter & Stay Updated
